Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Expert Opinion on Drug Metabolism & Toxicology

• Publication date

  2016-06-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/17425255.2016.1198317PMID 27284682
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abstract PD5-05: Neratinib forERBB2mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial

  2016cited by this paper
• Abstract S5-05: Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study

  2016cited by this paper
• Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

  2016cited by this paper
• Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

  2016influential reference
• Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.

  2016cited by this paper
• Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.

  2016cited by this paper
• Abstract S5-02: Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: 3-year analysis from a phase 3 randomized, placebo-controlled, double-blind trial (ExteNET)

  2016cited by this paper
• Effective Management and Prevention of Neratinib-Induced Diarrhea

  2015cited by this paper
• Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

  2015cited by this paper
• HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer

  2015cited by this paper
• Phase III, randomized study of trastuzumab emtansine (T-DM1) {+/-} pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.

  2015cited by this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2015cited by this paper
• Abstract P5-19-04: A phase I/II study of neratinib plus temsirolimus in HER2+ metastatic breast cancer reveals ongoing HER2 pathway dependence in many patients despite several lines of HER2 targeted therapy

  2015influential reference
• Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.

  2015cited by this paper
• Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study

  2015cited by this paper
• Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.

  2014cited by this paper
• Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

  2014cited by this paper
• ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

  2014cited by this paper
• Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.

  2014cited by this paper
• Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer

  2014cited by this paper
• Abstract CT227: Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL

  2014cited by this paper
• LBA39_PRNERATINIB (N) WITH OR WITHOUT TEMSIROLIMUS (TEM) IN PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING HER2 SOMATIC MUTATIONS: AN INTERNATIONAL RANDOMIZED PHASE II STUDY

  2014cited by this paper
• Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

  2014cited by this paper
• Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.

  2013cited by this paper
• Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

  2013cited by this paper
• Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer

  2013influential reference
• Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study

  2013cited by this paper
• Activating HER2 mutations in HER2 gene amplification negative breast cancer.

  2013influential reference
• Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer

  2013cited by this paper
• An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models

  2013cited by this paper
• A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.

  2013cited by this paper
• 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumours

  2013cited by this paper
• CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).

  2013cited by this paper
• Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

  2013cited by this paper
• Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.

  2012cited by this paper
• Neratinib Reverses ATP-Binding Cassette B1-Mediated Chemotherapeutic Drug Resistance In Vitro, In Vivo, and Ex Vivo

  2012cited by this paper
• A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor

  2012cited by this paper
• Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

  2012cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study.

  2012cited by this paper
• Trastuzumab emtansine for HER2-positive advanced breast cancer.

  2012cited by this paper
• National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

  2012cited by this paper
• Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

  2012cited by this paper
• Adjuvant trastuzumab in HER2-positive breast cancer.

  2011cited by this paper
• Comprehensive analysis of kinase inhibitor selectivity

  2011cited by this paper
• Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

  2011cited by this paper
• Resistance to HER2-directed antibodies and tyrosine kinase inhibitors

  2011cited by this paper
• Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.

  2011influential reference
• Metastatic behavior of breast cancer subtypes.

  2010cited by this paper
• Primary trastuzumab resistance: new tricks for an old drug

  2010cited by this paper
• Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial

  2010cited by this paper
• Characterization of HKI-272 Covalent Binding to Human Serum Albumin

  2010cited by this paper
• A Single-Dose, Crossover, Placebo- and Moxifloxacin-Controlled Study to Assess the Effects of Neratinib (HKI-272) on Cardiac Repolarization in Healthy Adult Subjects

  2010cited by this paper
• Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

  2010cited by this paper
• Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

  2010cited by this paper
• Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

  2010influential reference
• A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

  2009influential reference
• Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: A phase I/II study.

  2009cited by this paper
• Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

  2009cited by this paper
• Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

  2009cited by this paper
• High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

  2009cited by this paper
• Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

  2009cited by this paper
• The Development of HKI‐272 and Related Compounds for the Treatment of Cancer

  2008cited by this paper
• The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

  2007cited by this paper
• Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study

  2007cited by this paper
• Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab

  2006cited by this paper
• An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.

  2006cited by this paper
• Herceptin: mechanisms of action and resistance.

  2006cited by this paper
• Somatic Mutations of ERBB2 Kinase Domain in Gastric, Colorectal, and Breast Carcinomas

  2006cited by this paper
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  2006cited by this paper
• ErbB receptors: new insights on mechanisms and biology.

  2006influential reference
• Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

  2006cited by this paper
• Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.

  2006cited by this paper
• Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

  2005cited by this paper
• Adjuvant trastuzumab for HER2-positive breast cancer.

  2005cited by this paper
• Role of HER2/HER3 co-receptor in breast carcinogenesis.

  2005cited by this paper
• Antitumor activity of HER-2 inhibitors.

  2005cited by this paper
• Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

  2004influential reference
• Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

  2003cited by this paper
• The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

  2002cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Grb2 and Shc Adapter Proteins Play Distinct Roles in Neu (ErbB-2)-Induced Mammary Tumorigenesis: Implications for Human Breast Cancer

  2001cited by this paper
• The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.

  1999cited by this paper
• ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

  1997cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper

• In-vitro and In-vivo CYP3A4 Variants: Neratinib Metabolism and Drug Interaction Risk.

  2026cites this paper
• Blautia luti reduces neratinib-induced diarrhea in a rat model

  2025cites this paper
• Neratinib for HER2-positive breast cancer with an overlooked option

  2023cites this paper
• Advances in understanding the role and mechanisms of tumor stem cells in HER2-positive breast cancer treatment resistance (Review)

  2023cites this paper
• The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer

  2023cites this paper
• UPLC-MS/MS Method for Simultaneous Estimation of Neratinib and Naringenin in Rat Plasma: Greenness Assessment and Application to Therapeutic Drug Monitoring

  2023cites this paper
• An Insight into Molecular Targets of Breast Cancer Brain Metastasis

  2022cites this paper
• Drug repositioning based on gene expression data for human HER2-positive breast cancer.

  2021cites this paper
• Therapeutic Drug Monitoring of Protein Kinase Inhibitors in Breast Cancer Patients.

  2021cites this paper
• Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer

  2021cites this paper
• Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer.

  2020cites this paper
• Sodium-Dependent Glucose Transporter 1 (SGLT1) Stabled by HER2 Promotes Breast Cancer Cell Proliferation by Activation of the PI3K/Akt/mTOR Signaling Pathway in HER2+ Breast Cancer

  2020cites this paper
• A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer

  2020cites this paper
• Pan-cancer landscape and functional analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity

  2020cites this paper
• Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.

  2019cites this paper
• Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer

  2019influential citation
• Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

  2018cites this paper
• The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells

  2018cites this paper
• Study of Interactions of an Anticancer Drug Neratinib With Bovine Serum Albumin: Spectroscopic and Molecular Docking Approach

  2018cites this paper
• Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs.

  2018cites this paper
• Neratinib for the treatment of HER2-positive early stage breast cancer

  2017cites this paper
• Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib

  2017cites this paper
• ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology

  2017cites this paper
• Adjuvant trastuzumab: a 10-year overview of its benefit

  2017cites this paper
• Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer

  2016cites this paper
• ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast

  2016cites this paper